Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. More Details
Flawless balance sheet and slightly overvalued.
Share Price & News
How has Intellia Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NTLA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: NTLA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
7 Day Return
1 Year Return
Return vs Industry: NTLA exceeded the US Biotechs industry which returned 21.7% over the past year.
Return vs Market: NTLA exceeded the US Market which returned 55% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Intellia Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 days ago | Simply Wall StCompanies Like Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Invest In Growth
1 month ago | Simply Wall StBroker Revenue Forecasts For Intellia Therapeutics, Inc. (NASDAQ:NTLA) Are Surging Higher
1 month ago | Simply Wall StIntroducing Intellia Therapeutics (NASDAQ:NTLA), The Stock That Soared 360% In The Last Year
Is Intellia Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NTLA ($67.41) is trading below our estimate of fair value ($298.47)
Significantly Below Fair Value: NTLA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NTLA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: NTLA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NTLA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NTLA is overvalued based on its PB Ratio (8.5x) compared to the US Biotechs industry average (3.6x).
How is Intellia Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NTLA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NTLA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NTLA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NTLA's revenue (45.6% per year) is forecast to grow faster than the US market (9.7% per year).
High Growth Revenue: NTLA's revenue (45.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NTLA is forecast to be unprofitable in 3 years.
How has Intellia Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NTLA is currently unprofitable.
Growing Profit Margin: NTLA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NTLA is unprofitable, and losses have increased over the past 5 years at a rate of 32.6% per year.
Accelerating Growth: Unable to compare NTLA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NTLA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.3%).
Return on Equity
High ROE: NTLA has a negative Return on Equity (-25.47%), as it is currently unprofitable.
How is Intellia Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: NTLA's short term assets ($616.5M) exceed its short term liabilities ($64.3M).
Long Term Liabilities: NTLA's short term assets ($616.5M) exceed its long term liabilities ($85.0M).
Debt to Equity History and Analysis
Debt Level: NTLA is debt free.
Reducing Debt: NTLA has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NTLA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: NTLA has sufficient cash runway for 2.8 years if free cash flow continues to reduce at historical rates of 33.9% each year.
What is Intellia Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NTLA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NTLA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NTLA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NTLA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NTLA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Leonard (63 yo)
Dr. John M. Leonard, M.D., is an Executive Partner at Tyree & D'Angelo Partners. He has been a Director at IQVIA Holdings Inc. since February 2015 and has been its Lead Director since July 25, 2018. Dr. Le...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD903.79K) is below average for companies of similar size in the US market ($USD5.15M).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
Experienced Management: NTLA's management team is considered experienced (3.3 years average tenure).
Experienced Board: NTLA's board of directors are considered experienced (6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 34.1%.
Intellia Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Intellia Therapeutics, Inc.
- Ticker: NTLA
- Exchange: NasdaqGM
- Founded: 2014
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$4.565b
- Shares outstanding: 67.73m
- Website: https://www.intelliatx.com
Number of Employees
- Intellia Therapeutics, Inc.
- 40 Erie Street
- Suite 130
- United States
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRIS...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/22 15:03|
|End of Day Share Price||2021/04/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.